Shasun Pharma Peer Comparison

NSE: SHASUNPHAR | BSE: 524552

₹428.55

₹21.95 (5.40%)

As on 17-Nov-2015IST

Market cap

₹2,884 Cr

Revenue (TTM)

₹1,074 Cr

P/E Ratio

63.8

P/B Ratio

Div. Yield

0 %

Edit

	Shasun Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Market cap (₹ Cr)	2,884	29,435	27,409	25,981	24,746
Revenue (₹ Cr)	1,074	3,564	1,462	9,205	1,936
Net Profit (₹ Cr)	44.72	414.00	387.35	-371.81	288.22
Net Margin (%)	4.11	11.23	26.01	-3.93	14.79
RoE (%)	10.33	8.38	25.18	-3.85	29.77
Price to Earnings	63.83	71.97	70.97	--	85.86
Price-To-Book	5.99	5.85	15.89	3.25	18.44

Income Statement (₹ Cr)

	Shasun Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Operating Revenue	1,316.63	4,481.54	111.75	--	39.21
Total Income	1,328.86	4,548.09	111.77	--	39.54
Total Expenditure	1,196.75	3,772.14	103.45	--	28.05
EBITDA	119.87	709.40	8.29	--	11.16
Depreciation	46.96	145.40	0.72	--	5.18
EBIT	72.91	564.00	7.58	--	5.98
Interest	62.82	55.21	1.59	--	2.37
Other Income	12.23	66.55	0.02	--	0.33
Exceptional Items	7.85	49.83	--	--	--
Profit before Tax	30.17	575.34	6.01	--	3.94
Provision for Tax	6.33	162.65	1.91	--	1.27
Profit after Tax	23.84	412.69	4.10	--	2.67

	Shasun Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Shareholder's Funds	378.74	3,715.35	14.83	--	47.49
Minority Interest	--	143.95	--	--	--
Non-Current Liabilities	182.64	1,872.46	6.27	--	11.98
Current Liabilities	908.61	1,772.97	37.80	--	24.42
Total Liabilities	1,482.25	7,504.73	59.21	--	83.90

	Shasun Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Non-Current Assets	683.88	3,983.17	11.26	--	53.02
Current Assets	784.37	3,521.56	47.65	--	30.88
Total Assets	1,482.25	7,504.73	59.21	--	83.90
Total Debt*	739.46	2,010.07	22.92	--	26.03
Net Current Assets	-124.24	1,748.59	9.84	--	6.46
Contingent Liabilities	187.61	295.45	--	--	4.70

	Shasun Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Cash From Operating Activities	84.18	354.96	-3.88	--	10.55
Cash Flow from Investing Activities	-144.63	-206.63	-4.44	--	-5.46
Cash from Financing Activities	50.97	-75.65	8.61	--	-10.21
Net Cash Inflow / Outflow	-9.48	72.68	0.29	--	0.34

	Shasun Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
ROCE (%)	8.82	11.25	25.03	--	9.04
ROE (%)	7.25	12.49	31.99	--	9.82
ROA (%)	1.71	5.84	8.42	--	3.33
EBIT Margin (%)	10.03	17.31	7.44	--	29.29
Net Margin (%)	1.79	9.07	3.66	--	6.75
Cash Profit Margin (%)	5.24	12.43	4.31	--	19.93

	Shasun Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Revenue Growth (%)	8.57	-7.22	46.82	--	-5.70
EBIT Growth (%)	0.02	-27.08	24.42	--	-2.08
Net Profit Growth (%)	-21.17	-51.03	42.98	--	-40.70
EPS Growth (%)	-25.95	-42.48	42.98	--	-40.70
Book Value Growth (%)	18.82	4.11	37.67	--	10.33

	Shasun Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Price / Earnings	93.92	46.73	0.00	--	0.00
Price / Book Value	6.25	6.09	0.00	--	0.00
Dividend Yield (%)	0.00	1.07	--	--	--
EV/EBITDA	22.46	27.84	2.87	--	4.00
Market Cap (₹ Cr)	2,230.94	20,529.92	0.00	--	0.00

	Shasun Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debt to Equity	2.07	0.55	1.55	--	0.55
Short term debt to equity ratio	1.24	0.09	0.97	--	0.27
Current Ratio	0.86	1.99	1.26	--	1.26
Quick Ratio	0.60	1.41	0.89	--	1.22
Interest Coverage	1.48	11.42	4.78	--	2.66

	Shasun Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debtors to sales (%)	26.40	16.54	21.80	--	42.87
Asset Turnover	0.97	0.64	2.30	--	0.49
Receivable days	94.19	49.71	61.92	--	143.12
Inventory Days	59.78	81.88	41.26	--	10.03
Payable days	85.59	136.23	94.00	--	216.06
Cash Conversion Cycle	68.38	-4.64	9.17	--	-62.91

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.